Paliperidone
- Generic Name
- Paliperidone
- Brand Names
- Invega, Invega Hafyera, Xeplion, Niapelf, Byannli (previously Paliperidone Janssen-Cilag International), Trevicta (previously Paliperidone Janssen), ERZOFRI
- Drug Type
- Small Molecule
- Chemical Formula
- C23H27FN4O3
- CAS Number
- 144598-75-4
- Unique Ingredient Identifier
- 838F01T721
- Background
Paliperidone is the primary active metabolite of risperidone. The mechanism of action is unknown but it is likely to act via a similar pathway to risperidone. It has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2 (5HT2A) receptor antagonism. Paliperido...
- Indication
As an oral extended-release tablet and a once-monthly extended-release suspension for intramuscular injection, paliperidone is indicated for the treatment of adults and adolescents with schizophrenia and in the treatment of schizoaffective disorder in combination with antidepressants or mood stabilizers. Paliperidone is also available in both an every-three-...
- Associated Conditions
- Schizoaffective Disorders, Schizophrenia
- Associated Therapies
- -
Multidisciplinary Design to Optimize Schizophrenia Treatment Based on Multi-omics Data and Systems Biology Analysis
- Conditions
- Interventions
- First Posted Date
- 2023-09-29
- Last Posted Date
- 2023-09-29
- Target Recruit Count
- 244
- Registration Number
- NCT06060886
Early Predictors of Poor Treatment Response in Patients With Schizophrenia Treated With Atypical Antipsychotics
- Conditions
- Interventions
- First Posted Date
- 2018-11-05
- Last Posted Date
- 2019-02-15
- Lead Sponsor
- Calo Psychiatric Center
- Target Recruit Count
- 111
- Registration Number
- NCT03730857
A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication
- First Posted Date
- 2018-06-15
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 233
- Registration Number
- NCT03557931
- Locations
- 🇺🇸
CNS Research Science, Inc., Jamaica, New York, United States
🇺🇸Synergy East, Lemon Grove, California, United States
🇺🇸Pacific Research Partners, LLC, Oakland, California, United States
Substance Misuse To Psychosis for Stimulants
- First Posted Date
- 2018-04-02
- Last Posted Date
- 2023-07-05
- Lead Sponsor
- The University of Hong Kong
- Target Recruit Count
- 240
- Registration Number
- NCT03485417
- Locations
- 🇭🇰
Queen Mary Hospital, Hong Kong, Hong Kong
A Clinical Study to Evaluate the Bioavailability Between Two Products Containing Paliperidone 100 mg in the Form of a Prolonged Release Suspension for Injection in Patients With Schizophrenia Who Are Already Stabilized in This Treatment
- First Posted Date
- 2018-02-07
- Last Posted Date
- 2019-07-19
- Lead Sponsor
- Pharmathen S.A.
- Target Recruit Count
- 70
- Registration Number
- NCT03425552
- Locations
- 🇯🇴
Al-Esraa Hospital, Amman, Jordan
🇯🇴King Abdullah University Hospital, Ar Ramtha, Jordan
🇯🇴Princes Basma Teaching Hospital, Irbid, Jordan
Long-acting Paliperidone Palmitate Injection and Olanzapine for Schizophrenia
- First Posted Date
- 2016-09-29
- Last Posted Date
- 2018-01-18
- Lead Sponsor
- Beijing HuiLongGuan Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT02918825
- Locations
- 🇨🇳
Beijing HuiLongGuan Hospital, Beijing, China
Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies
- Conditions
- First Posted Date
- 2016-09-08
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- University of New Mexico
- Target Recruit Count
- 1037352
- Registration Number
- NCT02893371
- Locations
- 🇺🇸
Christophe G Lambert, Albuquerque, New Mexico, United States
Whole Blood and Plasma Sample Collection for the Development of Antipsychotic Immunoassays From Participants Taking Aripiprazole, Olanzapine, Paliperidone, or Risperidone
- Conditions
- Interventions
- First Posted Date
- 2015-12-18
- Last Posted Date
- 2018-04-18
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 81
- Registration Number
- NCT02634463
Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)
- Conditions
- Interventions
- Other: Caregiver psycho-education and skills trainingOther: Caregiver support available at the study siteDrug: Paliperidone palmitateDrug: ChlorpromazineDrug: DroperidolDrug: FluphenazineDrug: HaloperidolDrug: LoxapineDrug: PerphenazineDrug: PimozideDrug: ProchlorperazineDrug: ThiothixeneDrug: ThioridazineDrug: TrifluoperazineDrug: AripiprazoleDrug: AsenapineDrug: ClozapineDrug: IloperidoneDrug: OlanzapineDrug: PaliperidoneDrug: QuetiapineDrug: RisperidoneDrug: Ziprasidone
- First Posted Date
- 2015-11-09
- Last Posted Date
- 2019-01-23
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Target Recruit Count
- 296
- Registration Number
- NCT02600741
A Study to Assess the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry
- Conditions
- Interventions
- First Posted Date
- 2015-06-04
- Last Posted Date
- 2017-03-29
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 9
- Registration Number
- NCT02462473
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.